Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 and Temozolomide in Advanced Pancreatic Neuroendocrine Tumors
NCT00576680Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2008
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Started May 2008; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT00576680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576680.